Recruiting

N/A

100

 

neoadjuvant Docetaxel/Oxaliplatin/Xelode (DOX) ;Neoadjuvant Docetaxel/Oxaliplatin/Xelode (DOX) three weeks and eight weeks courses

the First Affiliated Hospital of Nanjing Medical University; the First Affiliated Hospital of Nanjing Medical University, research fund from department of gastric surgery

gastric cancer

 

 

Completed

N/A

30

 

Treated with Gemcitabine, oxaliplatin and dexamethasone (GOD) regimen

Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Level of the institution：, Scientific Research Program from Health Bureau of Shanghai (grant no.2010101).

relapsed or refractory peripheral T-cell lymphoma

 

 

Completed

N/A

1285

 

six commonly used regimens (i.e. CF/XP; EC(O)F/EC(O)X; DC(O)F/DC(O)X; PC(O)F/PC(O)X; FOLFOX4; mFOLFOX7/XELOX)

Gastrointestinal Oncology Department, Affiliated Cancer Center of Academy of Military Medical Sciences; Gastrointestinal Oncology Department, Affiliated Cancer Center of Academy of Military Medical Sciences, SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD, Shenyang, China; Affiliated hospital of Academy of Military Medical Sciences

Gastric Cancer

 

 

Active, not recruiting

N/A

57

NA

RAPIDO TNT, LCRT

Sengkang General Hospital

Rectal Cancer

05/22

06/24

Recruiting

N/A

300

 

Preoperative chemotherapy of DOX for 4 cycles, capecitabine 1000mg/m2, bid, p.o, 1 to 14 days; oxaliplatin 130mg/m2, ivgtt, 2h, d1, docetaxel 60mg/m2, ivgtt, d1, 21 day/cycle, operation after 2~4 weeks, and postoperative chemotherapy of XP for 4cycles after surgery ;Preoperative chemotherapy of XP for 4 cycles, capecitabine 1000mg/m2, bid, p.o, 1 to 14 days; oxaliplatin 130mg/m2, ivgtt, 2h, d1, 21 day/cycle, operation after 2~4 weeks, and postoperative chemotherapy of XP for 4cycles after surgery ;Operation after 2~4 weeks, and postoperative chemotherapy of XP for 8cycles after surgery, capecitabine 1000mg/m2, bid p.o, 1 to 14 days; oxaliplatin 130mg/m2, ivgtt, 2h, d1

Hebei Medical University affiliated Fourth Hospital; Hebei Medical University affiliated Fourth Hospital, self-raise

Advanced gastric cancer

 

 

Recruiting

N/A

500

 

NA

81 Hospital of Chinese PLA; Level of the institution：, Sanofi (Hangzhou) Pharmaceuticals Co., Ltd

Hepatocellular Carcinoma

 

 

Recruiting

N/A

80

 

EGCG(epigallocatechin gallate) + chemotherapy ;chemotherapy

Cancer Hospital of Shantou University Medical College; Cancer Hospital of Shantou University Medical College, Scientific research project of traditional Chinese Medicine Bureau of Guangdong Provincial

Gastric Cancer

 

 

Recruiting

N/A

100

RoW

NACT, SDM, Surgery, ACT, Questionnaire

Peking University

Gastric Cancer

01/19

01/23

Active, not recruiting

N/A

19

US

Fat Emulsion, FAT EMULSION, INTRAVENOUS, Intralipid, Intravenous Fat Emulsion, Placebo, placebo therapy, PLCB, sham therapy

Mayo Clinic, National Cancer Institute (NCI)

Advanced Malignant Neoplasm

07/19

12/24

Recruiting

N/A

166

RoW

Laparoscopic D2 distal gastrectomy

West China Hospital, Peking University Cancer Hospital & Institute, Southern Medical University, China, Shanghai Zhongshan Hospital, Chinese PLA General Hospital, Fujian Medical University Union Hospital, Ruijin Hospital, Southwest Hospital, China, RenJi Hospital, The First Affiliated Hospital with Nanjing Medical University, Fudan University, Tang-Du Hospital, Harbin Medical University, The First Hospital of Jilin University, Guangdong Provincial People's Hospital, Sir Run Run Shaw Hospital

Complications, Postoperative, Surgery--Complications, Cancer of Stomach, Chemotherapy Effect

04/20

04/23

Recruiting

N/A

48

 

Trastuzumab XELOX and radiotherapy ;XELOX and radiotherapy

Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University, self-raised

adenocarcinoma at gastroesophageal junction

 

 

Recruiting

N/A

60

Europe

PIPAC with oxaliplatin, Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy, CRS and HIPEC

University Hospital Tuebingen, Icahn School of Medicine at Mount Sinai

Peritoneal Cancer, Chemotherapy-Induced Change

09/20

09/22

Recruiting

N/A

100

RoW

Shanghai Jiao Tong University School of Medicine

Cholangiocarcinoma of the Bile Duct

12/20

12/21

Recruiting

N/A

50

 

continuous hepatic artery infusion of oxaliplatin combined with retitrexide

Fujian Cancer Hospital; Fujian Cancer Hospital, institution funding

Hepatocellular Carcinoma

 

 

Recruiting

N/A

348

 

LBP combined with capecitabine ;Oxaliplatin combined with capecitabine

The first hospital of China medical university; Anhui provincial hospital, Hainan Changan International Pharmaceutical Co., Ltd.

Stomach cancer

 

 

Recruiting

N/A

300

RoW

Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab

Sun Yat-sen University

Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy

12/24

12/24

Completed

N/A

188

RoW

Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy

Sun Yat-sen University

Hepatocellular Carcinoma

07/23

07/23

Recruiting

N/A

350

RoW

transarterial infusion

Sun Yat-sen University

Hepatocellular Carcinoma

06/21

12/22

Recruiting

N/A

304

RoW

Staging laparoscopy, 5-Fluorouracil, 5-FU, Leucovorin, Calciumfolinat, Oxaliplatin, Docetaxel, Radical surgery, PIPAC, Adjuvant chemotherapy

St. Petersburg State Pavlov Medical University

Peritoneal Carcinomatosis, Gastric Cancer

10/21

01/29

Not yet recruiting

N/A

370

RoW

the level of vWF

Shanghai Zhongshan Hospital

Gastroesophageal Varices, Colorectal Cancer, Received Oxaliplatin-based Chemotherapy

10/21

09/22

Recruiting

N/A

30

 

The albumin binding paclitaxel + teggio/gemcitabine + oxaliplatin regimen was sequential and alternating

Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself

Locally advanced and metastatic pancreatic cancer

 

 

Completed

N/A

30

RoW

Hepatic arterial infusion chemotherapy, Lenvatinib, TKI inhibits, Sintilimab, programmed cell death protein-1 (PD-1) antibody

Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University

Carcinoma, Hepatocellular, Liver Neoplasms, Sintilimab, Portal Vein Tumor Thrombus

12/21

12/22

Recruiting

N/A

66

Europe

Hilotherapy

Universitaire Ziekenhuizen Leuven

Quality of Life, Chemotherapy-induced Peripheral Neuropathy

12/21

05/22

Recruiting

N/A

20

RoW

FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)

Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanghai Junshi Bioscience Co., Ltd.

Chemotherapy, Gastric Cancer

05/22

05/23

Not yet recruiting

N/A

100

 

Oxaliplatin-based chemotherapy, education disease related knowledge and He-Xue Tong-Bi Powder will be used ;Oxaliplatin-based chemotherapy and education disease related knowledge will be used

The First Affiliated Hospital of Guangzhou University of Chinese Medicine; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, 'Dengfeng hospital' plan of the First Affiliated Hospital of Guangzhou University of traditional Chinese Medicine

Colorectal cancer

 

 

Not yet recruiting

N/A

150

 

irinotecan DEB-TACE with GEMOX ;GEMOX treatment

Zhongshan Hospital of Fudan University; Zhongshan Hospital of Fudan University, Fund for Clinical Research, Zhongshan Hospital of Fudan University

intrahepatic cholangiocarcinoma

 

 

Completed

N/A

72

RoW

Surufatinib combine immune checkpoint inhibitor, AG/FOLFIRINOX

Luo Cong

Pancreatic Cancer

07/23

04/24

Active, not recruiting

N/A

121

Europe

Capecitabine, Oxaliplatin, Bevacizumab

Istituto Oncologico Veneto IRCCS

Elderly Metastatic Colorectal Cancer Patients

07/24

12/24

Not yet recruiting

N/A

262

 

Insect compound Particels combined with mfolfox6 ;Placebo of Insect compound Particles combined with mfolfox6

Shanghai Municipal Hospital of Traditional Chinese Medicine; Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai Shenkang Hospital Development Center

colorectal cancer

 

 

Not yet recruiting

N/A

300

 

Hongai Tongluo decoction combined with Du moxibustion and chemotherapy ;Chemotherapy

Shanghai Longhua University Hospital of traditional Chinese Medicine; Shanghai Longhua University Hospital of traditional Chinese Medicine, Special funds

Digestive tract tumor

 

 

Recruiting

N/A

84

 

acupuncture ;sham acupuncture

Hospital of Chengdu University of Traditional Chinese Medicine; Hospital of Chengdu University of Traditional Chinese Medicine, Special funds

Oxaliplatin-induced peripheral neurotoxicity

 

 

Recruiting

N/A

120

 

Apatinib 250mg po, qd, continuous taken; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w ;Bevacizumab 7.5mg/kg, q3w; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w

Tangshan People's Hospital; Tangshan people's Hospital, self-raise

colorectal cancer

 

 

Recruiting

N/A

124

RoW

Lenalidomide, Rituximab, Gemcitabine, oxaliplatin

The First Affiliated Hospital with Nanjing Medical University

Diffuse Large B Cell Lymphoma

12/22

12/24

Not yet recruiting

N/A

184

RoW

FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).

Eastern Hepatobiliary Surgery Hospital

Hepatocellular Carcinoma

12/22

12/23

Not yet recruiting

N/A

98

NA

Transcatheter arterial chemoembolization, TACE Thrapy, Multi-target Drug Therapy, Target Therapy, Immunocheckpoint Inhibitor Therapy, Immune Therapy, Systemic Intravenous Chemotherapy, Traditional Chemotherapy

The Central Hospital of Lishui City

Intrahepatic Cholangiocarcinoma

12/22

12/23

Not yet recruiting

N/A

176

NA

Hepatic Artery Infusion Chemotherapy, HAIC, Transarterial Chemoembolization, TACE, Regorafenib, second-line target drug, Immune Checkpoint Inhibitors, Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, Toripalimab

The Central Hospital of Lishui City

Hepatocellular Carcinoma

02/23

02/25

Completed

N/A

140

NA

Fluorouracil, Aflibercept, ZALTRAP®, Irinotecan, CAMPTOSAR®

Sanofi

Metastatic Colorectal Cancer, Colorectal Neoplasms

05/22

05/22

Recruiting

N/A

30

 

Camrelizumab + apatinib + ticgio + oxaliplatin

The Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd

gastric cancer

 

 

Active, not recruiting

N/A

40

Europe

Foot reflexology

University Hospital, Toulouse

Colorectal Cancer

12/24

12/25

Recruiting

N/A

70

Europe

Photobiomodulation

Saint-Gregoire Private Hospital Center

Cancer of the Gastrointestinal Tract

03/25

04/25

Recruiting

N/A

50

RoW

Doublet or triplet chemotherapy combined with cetuximab

Qilu Hospital of Shandong University

Colon Cancer

12/24

12/25

Not yet recruiting

N/A

57

NA

Penpulimab combination with anlotinib and chemotherapy, Teggio, Oxaliplatin

Xijing Hospital

Gastric Cancer

06/23

06/24

Recruiting

N/A

349

RoW

CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy

Sun Yat-sen University, Guangzhou Burning Rock Dx Co., Ltd.

Colorectal Cancer

07/28

07/28

Not yet recruiting

N/A

60

 

Camrelizumab Plus Apatinib ;Fluorouracil combined with oxaliplatin chemotherapy

Shengjing Hospital Affiliated to China Medical University; Shengjing Hospital Affiliated to China Medical University, Independent project

Hepatic Carcinoma

 

 

Recruiting

N/A

30

 

neoadjuvant chemotherapy

The First Affiliated Hospital of USTC WEST district; The First Affiliated Hospital of USTC WEST district, self-raised

gastric

 

 

Recruiting

N/A

200

RoW

Intratumoral Injection of Chemotherapy

Wuxi People's Hospital

Intratumoral Injection, Cancer

12/27

12/28

Not yet recruiting

N/A

152

 

Capecitabine + oxaliplatin ;Oxaliplatin

Fuwai Central China Cardiovascular Hospital; Fuwai Central China Cardiovascular Hospital, Fuwai Central China Cardiovascular Hospital

gastric cancer

 

 

Recruiting

N/A

8

 

Oxaliplatin + adriamycin (at least 2 mL) + BM601 lipiodol suspension (3 ml) hepatic artery embolization

Lishui Central Hospital; Suzhou Baimai Biomaterials & Pharmaceutics CO., LTD, Self-raised

Tumor

 

 

Enrolling by invitation

N/A

80

RoW

polymorphism analysis

Ain Shams University

Gastrointestinal Tract Cancer, Peripheral Neuropathy

02/24

04/24

Recruiting

N/A

85

RoW

MRD-guided therapy

Qilu Hospital of Shandong University, Shandong Provincial Hospital, Jinan Central Hospital, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University

Stage II-III Gastric Cancer

04/27

04/29